Posts by Mourabit Halima

"The continuous advancements and remarkable success of Highly Active Antiretroviral Therapy (HAART) have made long-term survival for HIV patients a reality. However, the persistent presence of the HIV virus, chronic inflammation associated with the virus, and the lifelong impact of medication have led to chronic complications, such as metabolic diseases, becoming significant factors affecting the clinical outcomes of patients undergoing long-term treatment. These issues have become crucial in the treatment and management of patients. One of the key focuses of the 25th International AIDS Conference (AIDS2024) was the ongoing attention to non-AIDS-related complications, which brought new insights into their treatment and management."

From July 22-26, 2024, the 25th International AIDS Conference（AIDS 2024） was held in Munich, Germany, bringing together 15,000 professionals and advocates from around the world to discuss the latest advancements and future challenges in HIV prevention and treatment. At the conference, Dr. Biao Zhu from the First Affiliated Hospital,Zhejiang University School of Medicine presented a retrospective study conducted by his team. The report analyzed the changing disease spectrum of hospitalized HIV-infected patients in comprehensive hospitals in Eastern China over the past 12 years, revealing not only the survival status of HIV-infected patients in the Yangtze River Delta region but also significant changes in their disease spectrum as they achieve long-term survival.

Since its inception in 2005, the Shanghai International Forum for Infection Control (SIFIC) has grown over the past two decades. Known for its professionalism and forward-thinking approach, SIFIC has become a significant academic platform in China for the fields of hospital infection, major infectious diseases, and the prevention and control of multidrug-resistant organisms. Each year's academic conference not only boasts a large scale but also serves as a grand academic gathering for infection control experts and scholars from both domestic and international arenas. In the recently concluded SIFIC 2024 conference, one of the founders and current Chairman of SIFIC, Dr. Bijie Hu from Zhongshan Hospital, Fudan University, shared with Infectious Disease Frontier the development and achievements of SIFIC, as well as his profound insights into the future of infection control in China. Through his perspective, we gain a glimpse into the evolution of the field, the challenges it currently faces, and the direction it is likely to take in the future.

The 25th International AIDS Conference (AIDS 2024) was held in Munich, Germany, from July 22 to 26, 2024. This highly anticipated academic event showcased some of the most cutting-edge research in the field. Currently, clinical cures for people co-infected with HIV and HBV are still in the exploratory stage. At the conference, a research study conducted by Dr. Jie Peng’s team from the Nanfang Hospital was selected for poster presentation. The study revealed that after receiving antiretroviral therapy, HIV/HBV co-infected patients had a higher rate of HBsAg clearance. Baseline HBsAg levels and CD4 cell counts were identified as predictive factors for HBsAg clearance in these patients. We have invited Dr. Jie Peng to provide an insightful interpretation of these research findings for our readers.